NasdaqGS:NBIXBiotechs
INGREZZA Data In Complex Patients Adds Support For Neurocrine Valuation Story
Neurocrine Biosciences (NasdaqGS:NBIX) reported new data on INGREZZA showing strong symptom improvements in tardive dyskinesia for patients with intellectual and developmental disabilities.
Additional analyses indicated meaningful benefits and remission rates in patients with hepatic impairment, a group that often faces limited dosing options.
The findings highlight functional gains and rapid symptom relief in challenging real world populations beyond the broader tardive dyskinesia...